Sucampo Pharmaceuticals, Inc. Uncategorized Contracts & Agreements
39 Contracts & Agreements
- AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on November 9, 2016)
- AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on November 9, 2016)
- AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on November 9, 2016)
- AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on November 9, 2016)
- AMENDED AND RESTATED EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on November 9, 2016)
- OPTION AND COLLABORATIONAGREEMENT (Filed With SEC on May 5, 2016)
- STRATEGIC ALLIANCE AGREEMENT dated as of August 26, 2015 among Sucampo Pharmaceuticals, Inc., Sucampo Pharma, LLC. and R-Tech Ueno, Ltd. (Filed With SEC on November 4, 2015)
- AMENDMENT NO. 1 TO AGREEMENT (Filed With SEC on November 7, 2014)
- Confidential1 Ryuji Ueno (Filed With SEC on March 12, 2014)
- EMPLOYMENTAGREEMENT (Filed With SEC on March 15, 2012)
- Agreement on Bank Overdrafts (Through an Account Used Exclusively for the Purpose of Bank Overdrafts) (Customer Copy) (Filed With SEC on March 8, 2011)
- Special Agreement (Filed With SEC on March 8, 2011)
- NON-COMPETITIONAGREEMENT (Filed With SEC on December 29, 2010)
- Condensed Consolidated Financial Statements (Unaudited) (Filed With SEC on November 6, 2009)
- Page 1 of 41 (Filed With SEC on May 11, 2009)
- [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of The... (Filed With SEC on May 11, 2009)
- ADDENDUM TO AMENDED AND RESTATED PATENT ACCESS AGREEMENT: REDUCTION OF ROYALTIES WITH RESPECT TO SPL TERRITORY (Filed With SEC on February 20, 2009)
- AMENDED AND RESTATED (Filed With SEC on December 11, 2008)
- INDEPENDENT CONTRACTOR AGREEMENT (Filed With SEC on July 28, 2008)
- SUCAMPO PHARMACEUTICALS, INC. (Filed With SEC on November 14, 2007)
- SPI-8811 (cobiprostone) for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders... (Filed With SEC on July 17, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders associated with... (Filed With SEC on June 25, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders associated with... (Filed With SEC on May 14, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and... (Filed With SEC on February 1, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and... (Filed With SEC on February 1, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and... (Filed With SEC on February 1, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and... (Filed With SEC on February 1, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and... (Filed With SEC on February 1, 2007)
- SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and... (Filed With SEC on February 1, 2007)
- Confidentialmaterials omitted and filed separately with the Securities andExchange Commission. Asterisks denote omissions. (Filed With SEC on October 25, 2006)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on October 25, 2006)
- Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on October 25, 2006)
- Amended and Restated (Filed With SEC on August 11, 2006)
- ConfidentialMaterials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on June 19, 2006)
- ConfidentialMaterials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on June 19, 2006)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on June 19, 2006)
- ConfidentialMaterials omitted and filed separately with the Securities and ExchangeCommission. Asterisks denote omissions. (Filed With SEC on June 19, 2006)
- Confidential Materials omitted and filed separately with the (Filed With SEC on June 19, 2006)
- 4733 BETHESDA AVENUE (Filed With SEC on June 19, 2006)
